Cancer Treatments / Symptoms & Support
The leading side effect of EGFR inhibitors, both the oral tyrosine kinase inhibitors (such as tarceva (erlotinib)) and the IV monoclonal antibodies (such as erbitux (cetuximab)), is rash, dryness, and other skin side effects. While a rash sounds modest to many people compared to many of the leading problems with chemo, […]
4 CommentsAs I’ve described in various posts about targeting the epidermal growth factor receptor (EGFR), one of the main signals that is important in many lung cancers, there are agents like gefitinib (iressa) and erlotinib (tarceva) that target the internal switch that triggers activity inside the cell, and there are agents like cetuximab […]
2 CommentsWe’ve been following the development of a drug called Zactima (also known as ZD6474, or vandetanib) for over a year as it continues to be studied in lung cancer, and the work continues. As first discussed in my initial post on this agent, this agent actually inhibits BOTH VEGF and EGFR […]
10 CommentsWhile there have been studies of the COX-2 inhibitor celebrex in combination with chemo for treating NSCLC, the palpable buzz about celebrex in treating lung cancer has been from a trial by my friend Karen Reckamp, formerly at UCLA, now recently moved to City of Hope Cancer Center in nearby Duarte, CA. […]
2 Comments
Posts
| Core Concepts
| Subject Archives
| Monthly Archives
| Resources
| 
Donate
| Forums
| GRACE Home
Disclaimer: The information provided at GRACE is for informational purposes only. The faculty of GRACE is not providing medical advice, diagnosis or treatment and cannot replace the medical advice of your doctor or health care provider. (Full Disclaimer)
© 2007-2008 GRACE. All rights reserved.
